Big 5 Reviews
Big 5 Reviews
Most UK riflemen would never get the chance or have the need to use a double rifle. More intriguing is that the intended quarry for this calibre would be more than capable of dispatching the person behind the butt if things did not go to plan. So why is the double rifle format so popular in Europe and abroad?
Around the 1900s, the double-barrelled rifle was apparently much cheaper than its early bolt-action equivalents. More importantly, there was less to go wrong in extreme conditions such as in Africa and India, where it was essential when dealing with dangerous game. They lost their appeal – no thanks to the two world wars, which accelerated the development of the multi-shot bolt action – but there has been a renewed interest in this classic design over the past 30 years.
They are safe, the action is easy to open but, most importantly, they are quick and uncomplicated to reload, not forgetting the simplicity of cleaning and ability to be taken apart for easy transportation. In the field, they are generally shorter than a normal bolt-action rifle, as the bolt action is not required, making them more pointable, but it is the ability to fire the second shot quickly that really drives the popularity of this design.
Enough of the history – I welcome you to the Krieghoff Big Five rifle in the uncompromising .470 Nitro Express calibre. The Classic Big Five is available in many larger calibres from the .375 H&H to the .500NE but, interestingly, a pair of 20-gauge barrels can be fitted if you want to test your skills with flying game.
Big 5 casino is known for providing more than 20 different blackjack games. These include variants such as American Blackjack, Blackjack Multihand VIP, Double Exposure Blackjack and more. But this is only one category, as there are poker games, baccarat, roulette, video poker, as well as scratch cards.
- See full list on big-5-sporting-goods.pissedconsumer.com.
- The Big 5 Protection Pack Contains - Interceptor Spectrum + Credelio Easy Way To Prevent 5 Prevailing Parasites + Tapeworm From Dogs. Click to download The Big 5 Protection Pack is an advanced treatment for dogs. It protects your dog in and out.
- 1,199 reviews from Big 5 Sporting Goods employees about Big 5 Sporting Goods culture, salaries, benefits, work-life balance, management, job security, and more.
As it’s a .470NE, you would have imagined this would be a large and heavy monster, but as I lifted it out of its case, I realised it wasn’t. While it has the feel of a solid but beautiful piece of German engineering, the boxlock design gives the impression of a slender shotgun, and when raised to the shoulder, it feels compact for a 10lb rifle.
The stock, made from the finest European walnut wood, oozes undeniable quality thanks to its deep and beautifully coloured grain, with delightful chequering on the wide pistol grip and forend. The design of this stock is critical for these heavy calibres, as it has a low-straight comb with a curved cheekpiece, all of which is designed to help with the greater recoil from standing.
Moving forward, the ‘combi-cocking’ lever dominates the top tang. This cocking lever allows the rifle to be carried when fully loaded, without the fear of an accidental discharge. As the ‘Big Five’ is raised to the shoulder, the thumb pushes this lever forward ready for firing, but does not automatically decock the firing mechanism when the action is broken for reloading. Some may say this is unsafe, but this is designed for dangerous game where reloading and subsequent shots must be executed in the fastest possible time. So you break the barrel, reload, raise it the shoulder and fire without the need to cock the action again. Simple and effective.
The action itself has reinforced walls for extra strength with high-quality ‘small Arabesque’ engraving to the sides. On to the two triggers: the front activates the right barrel and the rear the left, both set at 3½ to 4lb, aided by virtually horizontal firing pin placement for fast lock time. Most doubles have much heavier trigger pulls, but the patented Krieghoff Universal Trigger System prevents both barrels from being fired at the same time owing to heavy recoil – always a worry when lighter triggers are used. Interestingly, the front trigger is hinged to protect the trigger finger when shooting the rear trigger, as the recoil will push the rifle backwards, driving the front blade into the back of that finger.
As with any double-barrelled rifle, the ‘regulation’ – making sure that both barrels shoot the same point of impact – can be tricky to set up. On the .375 H&H or smaller calibre rifles, this is adjustable at the muzzle, but fixed at the factory for the larger calibres. Most doubles are set to a 50-yard zero and guarantee an accuracy of 2in at this distance using their factory-recommended ammunition. The 23.5in barrels on this model come with fixed front moon sights and an open ‘V’ to the rear on the raised central rib. As an extra option, I would recommend the folding express rear sights to help shooting at a variety of distances.
When breaking the action by using the top lever, the opening is very short, designed for very quick extraction – but this model does not come with extractors as standard. I spoke to Alan Rhone, who informed me that this is not always essential, as all one does is roll the rifle over to allow both spent cases to fall out, and then reload. Also, many hunters feel ejectors are another thing to go wrong – in other words, keep it simple.
Out came the huge Kynoch .470 Nitro Express rounds in solid and soft point, kindly supplied by Kynamco. My immediate thought was for my poor old shoulder, as these rounds have a 500-grain bullet, being pushed out at 2,150fps, not forgetting the 5,000ft/lb of energy. I put on an extra layer to give my lean frame a chance of being able to shoot more rifles in the future for this magazine.
With the use of sticks, the time of reckoning could not be put off any longer. I must admit I snatched the trigger on my first shot, but one can describe the recoil as a large but firm push, as opposed to an almighty kick as experienced with shooting, for instance, a .338 Lap Mag. Well, maybe it was a bit of both.
At 70 yards, I achieved a 3in group and with practice, I am sure I could improve, but eight shots was all that I could put up with without the need to rest my aching shoulder, let alone my starting to flinch in anticipation of the recoil. Krieghoff takes pride in the design of the stock, combined with the larger pistol grip, and folding front trigger blade, as all these features allow the rifle to handle the immense recoil very effectively. It seemed a little strange that the rifle had no ejectors, but as soon as it was tilted over, out slid the spent cases. I can understand why they are so popular in the close bush thanks to the short barrels, making it very pointable and easy to shoulder very quickly.
This is the first time I have tested a double rifle in .470 NE and I was pleased to have the opportunity, but I learned one important fact. You cannot expect to pick one up quickly and wander off into the bushveld thinking you will easily kill your quarry. Despite the immense power and simplicity of these rifles, lots of practice is essential. It does not matter if you have open or closed optical sights – to make an accurate shot, you need a technique that is somewhat different to the normal bolt-action rifle. It does not stop there – reloading under pressure, understanding the bullet drop over very short and longer distances, are important factors if you have a large angry beast running towards you.
These are specialised rifles that appeal to a small portion of hunters, but if you find the opportunity to pick one up, study the engineering and embellishments, and you will see why they have that special attraction. A sincere thanks to Kynamco for supplying the rather expensive ammunition for calibres such as this. TP
Model tested: Classic Big Five Double .470 NE
Price range: From £6,000
Contact: Alan Rhone 01978 660001 www.alanrhone.com
Ambu is expanding its product portfolio and commercial infrastructure. Today, we announce timelines for new aScope™ 5, a new ureteroscope, a new monitor platform that allows full HD quality and a replacement of the SC210 colonoscope for a superior scope based on classic wheel technology. Financial outlook adjusted to reflect commercial investments and new product launch timelines.
In October 2017, Ambu announced a three-year strategy plan called “Big Five 2020”. The Big Five strategy set the direction for further growth through a pipeline of new single-use endoscopes for a broad range of medical fields. We have now reviewed the strategy and decided to accelerate our investments in commercial infrastructure and further strengthen our global leadership in single-use Visualization. We are also providing an update on our product pipeline including new products, revised prioritization and launch dates. Finally, we also provide the impact of these decisions to the financial outlook for 2018/19 and 2019/20.
Lipogaine Big 5 Shampoo Reviews
INVESTMENTS IN COMMERCIAL INFRASTRUCTURE
As planned, Ambu will launch a range of new products across multiple endoscopy markets. In the short term, Ambu has recently launched two scopes into the ENT market which accounts for 11m procedures. In addition, the launch of the cystoscope into the urology market is expected to come earlier than expected. The urology market accounts for 8m procedures. Together with pulmonology, entering into ENT and urology represents a significant growth opportunity and opens a range of new call points across all markets. Therefore, we have decided to accelerate our investments in commercial infrastructure in the US, Europe and Asia Pacific with the purpose of maximizing the value and strengthen our position as a global leader in single-use Visualization. This investment plan will also support our partnership agreement with Cook Medical, which will further enhance Ambu’s ability to successfully enter into the market for duodenoscopy.
The total incremental cost is estimated to be DKK 225m in 2019/20 and covers approx. 200 additional sales reps, clinical trainers and an expansion of marketing capabilities in all our key markets. This expansion will more than double our global Visualization salesforce. To maximize the impact on growth in 2019/20 and beyond, hiring will start in Q4 2018/19 with an estimated cost in 2018/19 of approx. DKK 20m.
VISUALIZATION PORTFOLIO PIPELINE UPDATE
Lipogaine Big 5 Reviews
Monitor technology platform
One of the main drivers of single-use endoscopy is the quality of the image on the monitor. Over the last three years Ambu has been working with its exclusive technology partners to develop a modular architecture which will be the platform for our new portable monitors. We consider this platform to bring the most advanced full HD monitor on the market with significantly enhanced image quality (full HD: 1920x1080), more processing power, and improved functionality (dual view, LAN, WiFi, Bluetooth, HDMI, network connectivity, EMR integration).
This platform will be the basis for monitors to be used across our aScope product line and will support our growth potential going forward. The first two launches will be:
- aView™ 2 Advance: To be used for all aScopes within pulmonary, urology and ENT (expected launch Q3 2019/20)
- aBox™: To be used for all our new aScopes within the GI space (expected launch Q2 2020/21)
Pulmonary endoscopy
With the aScope™ 4 Broncho, Ambu has been able to successfully penetrate the ICU and OR suites reaching approx. 25% global share of the 3m pulmonary endoscopy market. Going forward, we have an opportunity to penetrate the bronch suite market which represents an incremental 2m procedures. The bronch suite has higher requirements with respect to image quality and functionality. We will therefore introduce aScope™ 5 Broncho which will be our first aScope with HD camera chip and an improved working channel. aScope™ 5 Broncho is expected to be commercially available in Q4 2020/21.
ENT
The ENT endoscopy market represents a significant opportunity with its 11m procedures. Ambu has recently launched two ENT scopes (aScope™ 4 RhinoLaryngo Intervention and Slim). We received FDA approval for the Slim version in May, 2019, and we are currently launching the product globally. The slim version targets 95% of the ENT market so this is a very important milestone for Ambu. We have launched the Intervention version in EU and Australia in our Q1 2018/19, and we expect to receive FDA approval by end of Q4 2018/19.
We have received positive feedback on the ENT scopes and expect to penetrate the ENT market at a faster pace compared to how aScope has historically performed within pulmonary endoscopy.
Urology
Urology represents another important market for Ambu with total procedures of 8m. We have shared before that we are developing a cystoscope to target bladder and urethra procedures which accounts for 6m out of the total 8m urology procedures. The cystoscope is expected to be launched in the US in Q2 2019/20, which is up to two quarters earlier than expected so far.
To complete our urology portfolio, we will be introducing a ureteroscope to target kidney procedures which account for 2m procedures where we expect to command higher selling price. We expect to be able to launch in the US in 2021/22. The combination of a single-use cystoscope and ureteroscope is ideal as physicians in many cases use both on the same patient.
Colonoscopy
With the acquisition of Invendo Medical in October 2017, Ambu acquired a technological platform for single-use GI scopes to be further developed. In addition, we got the fully developed single-use colonoscope SC210.
Since February, we have been testing the SC210 in a hospital setting in the US with the purpose of obtaining evidence that the SC210 will be able to perform to the standards of the reusable colonoscopes. When we started the test in the US, we expected to see a rapid uptake in the learning curve when using and navigating the SC210. Unfortunately, the results of tests were not satisfactory, and we have decided to discontinue the SC210.
In terms of the GI R&D program, the priority has been the development of the aScope™ Gastro and aScope™ Duo products. A second priority has been a single-use colonoscope based on the classic wheel technology (referred to as “aScope™ Colon”). With the decision to discontinue SC210, we will be able to focus more resources on the development of aScope™ Colon.
The main benefits of developing the aScope™ Colon as part of our aScope GI family are:
- Classic wheel technology which will drive faster physician adoption
- Our entire GI offering will share the same design which is important as two thirds of the colonoscopies are followed by a gastroscopy
- Unlike the SC210, the aScope™ Colon will share the aBox™ platform
The following are the expected launch dates for our aScope GI family:
- aScope™ Duo: Before end of September 2020
- aScope™ Gastro: Q2, 2020/21
- aScope™ Colon: Q2, 2020/21
FINANCIAL OUTLOOK
Current fiscal year (2018/19)
- Endoscopes sold (units) of approx. 750.000 compared to previously stated +750.000
- Organic growth of approx. 14-15% compared to previously stated 15-16%. The high comparable in Q3 2017/18 will reduce growth in Q3.
- EBIT-margin before special items of approx. 22% compared to previously stated 22-24%
- Free cash flows of approx. DKK 375m compared to previously stated DKK 400-475m
The reason for the adjustment of the growth is due to the discontinuation of the SC210. The adjustment of the EBIT margin is driven by the lower growth and the investments in commercial infrastructure. The adjustment to free cash flows is caused by the lower EBIT and a slightly increasing working capital. Special items related to replacement of Ambu’s CEO are unchanged and expected to be DKK 38m.
Big Five 2020 strategy (2019/20)
- Our expectation is to sell approx. 1.000.000 endoscopes units in 2019/20 compared to previously stated +1,000,000
- Organic growth in 2019/20 is estimated in the range of 16-19% compared to previously 18-23%
- EBIT margin before special items is estimated to be a minimum of 20% compared to previously 26-28%
- Free cash flows are estimated to be approx. 9% of revenue compared to previously approx. 18% of revenue
The reason for the reduction of the expected sale of endoscopes as well as the growth target by on average 3%-pts is primarily the discontinuing of the SC210. The adjustment to the EBIT-margin is on average 7%-pts. which is primarily explained by the additional investments into commercial infrastructure. The adjustment of the free cash flow-% is driven by the adjusted growth and EBIT-margin and impact from one-of tax payments.
A conference call is being held Tuesday 18 June 2019, at 8.30 (CEST). The conference is held in English and can be followed online at www.ambu.com/webcast18June2019. The presentation can be downloaded immediately before the conference call via the same link. In order to be able to ask questions during the conference call, please call 5 minutes before the start on tel. +45 3544 5577 and enter the following access code: 89439887#.
Furthermore, an investor meeting for analysts and institutional investors will be conducted in London on Wednesday 19 June, at 10.00 (BST). Enrolment can be done on www.ambu.com/London2019. The investor meeting will be broadcast live on video via the same link and will also be available for viewing after the event.
Attachment
Big 5 Reviews